1st Quarter - Report

JAZZ PHARMACEUTICALS, INC. for JAZZ PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$380,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

FDA regulation of CBD Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Farm, Food, and National Security Act Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act Drug safety, prescription drug abuse, value of prescription drugs Changes to the Inflation Reduction Act HR 946: Orphan Cures Act

LobbyistCovered position, as disclosed
MARK BOLTON —
KARAS GROSS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 946 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.